COMP <GO>
JAZZ vs MRK // EV/EBITDA & P/E VALUATION
Jazz Pharmaceuticals plc Common Stock (Ireland) (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: JAZZ 3
— MRK 10
■ METRIC PARITY
LAST: $215.98 (+3.92%) • MKT CAP: $13.49B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | 20.70% | -25.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | 3.42% | +6.19 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | 34.30% | -44.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -8.30% | 28.10% | -36.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.90% | 1.30% | +3.60 | JAZZ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.97 | 5.19 | -3.22 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.4 | 56.9 | -10.48 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.92 | +0.17 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 18.4x | +17.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.49B | $361.02B | -$347.53B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | MRK REV | JAZZ GROSS % | MRK GROSS % | JAZZ FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $65.01B | 44.0% | 74.8% | $1.30B | $12.36B |
| FY 2024 | $4.07B | $64.17B | 44.0% | 76.3% | $1.36B | $18.10B |
| FY 2023 | $3.83B | $60.12B | 44.0% | 44.0% | $919.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
MRK // BETA 0.92